Literature DB >> 15802457

Radiofrequency ablation therapy of remnant colorectal liver metastases after a course of hepatic arterial infusion chemotherapy.

Takuji Yamagami1, Takeharu Kato, Osamu Tanaka, Tatsuya Hirota, Tsunehiko Nishimura.   

Abstract

The present study evaluated the feasibility of combined therapy employing repeated hepatic arterial infusion chemotherapy (HAIC) via a port-catheter system and radiofrequency (RF) ablation for unresectable metastatic liver cancer from the colo-rectum. RF ablation was performed for six patients with liver malignancies that had been well controlled and had decreased in number and size with repeated HAIC. After RF ablation subsequent to repeated HAIC, all six patients had stable disease or complete or partial remission as documented by follow-up contrast-enhanced computed tomographic (CT) imaging. Fluorodeoxyglucose positron emission tomography (18F) showed complete response in all ablated lesions. In conclusion, RF ablation after a course of HAIC achieved complete necrosis in residual lesions after HAIC therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15802457     DOI: 10.1097/01.RVI.0000153439.89142.1D

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  3 in total

Review 1.  Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfusion: an update.

Authors:  Thomas J Vogl; Stephan Zangos; Katrin Eichler; Danny Yakoub; Mohamed Nabil
Journal:  Eur Radiol       Date:  2006-08-30       Impact factor: 5.315

Review 2.  [Combined therapies including interventional radiology].

Authors:  S Clasen; P L Pereira
Journal:  Radiologe       Date:  2007-12       Impact factor: 0.803

Review 3.  [Update on chemoinfusion and chemoembolization treatments].

Authors:  A Lubienski; M Simon; K Lubienski; J Gellissen; R-T Hoffmann; T F Jakobs; T Helmberger
Journal:  Radiologe       Date:  2007-12       Impact factor: 0.803

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.